Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper Sandler

Equities research analysts at Piper Sandler assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note issued on Friday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $48.00 price target on the stock.

AVTX has been the subject of several other reports. BTIG Research started coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush initiated coverage on shares of Avalo Therapeutics in a research report on Friday, February 21st. They issued an “outperform” rating and a $18.00 price objective on the stock. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $35.33.

Avalo Therapeutics Trading Down 1.5 %

AVTX stock opened at $6.60 on Friday. Avalo Therapeutics has a 1-year low of $4.28 and a 1-year high of $34.46. The business’s 50-day moving average price is $7.63 and its two-hundred day moving average price is $9.29.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new position in Avalo Therapeutics during the third quarter worth $9,186,000. Ikarian Capital LLC lifted its position in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares in the last quarter. Northern Trust Corp acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth about $168,000. Velan Capital Investment Management LP bought a new position in shares of Avalo Therapeutics in the 4th quarter valued at about $817,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the last quarter. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.